1. Scrip
  2. >>Business

Twin Gains For Novartis In India Ribociclib, Ceritinib Patent Cases

 
• By Anju Ghangurde

Novartis gains upper hand for now, staving off challenge to patents on its oncology drugs ribociclib and ceritinib in India by seasoned opponent Natco, though things appear far from over in the case.

Gavel scales law book (Proxima Studio/Shutterstock.com)
Court Rulings Give Novartis Upper Hand In Indian Patent Case • Source: Shutterstock

Novartis AG appears to have made legal gains versus challenger Natco Pharma Limited in India, successfully blocking, at least for now, an alleged infringement attempt for its anticancer ribociclib while also moving swiftly to get a previous restraining order for another oncology product, ceritinib, reinstated.

The case pertaining to ribociclib will require Natco to hold back commercial manufacturing of the breast cancer treatment, while the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.